This is a non-core endpoint: only basic statistics are computed.
See its core counterpart C3_CML_EXALLC for full statistics.
Chronic myeloid leukaemia
C3_CML
obsolete_chronic myeloid leukemia: ['Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.']
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
143 |
4. Check minimum number of eventsNone |
143 |
5. Include endpointsNone |
143 |
6. Filter based on genotype QC (FinnGen only) |
143 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- C
- First used in FinnGen datafreeze
- DF8
Similar endpoints
↥List of similar endpoints to
Chronic myeloid leukaemia
based on the number of shared cases.
Similar with more cases:
- Chronic myeloid leukaemia, excluding all cancers (controls excluding all cancers)
- Any event in cancer register
- Neoplasms
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 143 | 59 | 84 |
| Unadjusted period prevalence (%) | 0.03 | 0.02 | 0.04 |
| Median age at first event (years) | 57.92 | 54.96 | 60.00 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 142
- Matched controls
- 1420
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C92.1
ICD-10 Finland
Chronic myeloid leukaemia [CML], BCR/ABL-positive
+∞
201.9
141
*
9863/3-C42.1
ICD-O-3
Chronic myeloid leukemia, NOS, of bone marrow
+∞
164.1
124
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
1087.4
158.5
135
24
189
Kela drug reimbursment
Imatinib
+∞
131.4
105
*
L01XE01
ATC
[U] imatinib; oral
+∞
105.8
88
*
XW000
NOMESCO Finland
Bone marrow biopsy
66.3
66.7
76
24
L01XX05
ATC
hydroxycarbamide; oral
312.8
60.1
57
*
M04AA01
ATC
allopurinol; systemic
25.6
60.1
98
113
L01EA01
ATC
imatinib; oral (bcr-abl tyrosine kinase inhibitors)
+∞
51.1
46
*
316
Kela drug reimbursment
Imatinib
+∞
46.4
42
*
152
Kela drug reimbursment
Nilotinib
+∞
39.4
36
*
L01XX28
ATC
[D] imatinib; oral
+∞
33.7
31
*
D72.8
ICD-10 Finland
Other specified disorders of white blood cells
79.3
32.9
36
6
C92.0
ICD-10 Finland
Acute myeloblastic leukaemia [AML]
130.8
30.0
31
*
L01XE08
ATC
[U] nilotinib; oral
+∞
28.0
26
*
150
Kela drug reimbursment
Dasatinib
+∞
28.0
26
*
L01XE06
ATC
[U] dasatinib; systemic
+∞
24.7
23
*
212
Kela drug reimbursment
Gout
39.9
23.5
29
9
328
Kela drug reimbursment
Nilotinib
+∞
20.3
19
*
L01EA03
ATC
nilotinib; oral
+∞
20.3
19
*
C91.1
ICD-10 Finland
Chronic lymphocytic leukaemia of B-cell type
60.9
18.5
21
*
L01EA02
ATC
dasatinib; oral
+∞
18.1
17
*
324
Kela drug reimbursment
Dasatinib
+∞
18.1
17
*
9875/3-C42.1
ICD-O-3
Chronic myelogenous leukemia, BCR/ABL positive of bone marrow
+∞
18.1
17
*
127
Kela drug reimbursment
Transplant complication
23.3
15.7
22
11
L03AA02
ATC
filgrastim; parenteral
15.7
14.8
24
18
D75.9
ICD-10 Finland
Disease of blood and blood-forming organs, unspecified
+∞
11.6
11
*
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
38.4
11.5
14
*
A05AA02
ATC
ursodeoxycholic acid; oral
30.7
10.9
14
5
L04AA01
ATC
[U] ciclosporin; systemic
23.7
10.9
15
7
T86.0
ICD-10 Finland
Bone-marrow transplant rejection
+∞
10.5
10
*
D72.9
ICD-10 Finland
Disorder of white blood cells, unspecified
59.0
9.8
11
*
R50.9
ICD-10 Finland
Fever, unspecified
4.4
9.7
38
109
Y84
ICD-10 Finland
Other medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
39.3
9.1
11
*
L03AA04
ATC
NA
95.3
8.5
9
*
170
Kela drug reimbursment
Bosutinib
+∞
8.4
8
*
C92.9
ICD-10 Finland
Myeloid leukaemia, unspecified
+∞
8.4
8
*
WW500
NOMESCO Finland
Blood transfusion
9.3
8.0
16
19
C95.0
ICD-10 Finland
Acute leukaemia of unspecified cell type
47.5
7.8
9
*
121
Kela drug reimbursment
Severe hypofunction of sexual glands
14.4
7.5
12
9
B25.8
ICD-10 Finland
Other cytomegaloviral diseases
84.1
7.5
8
*
WW200
NOMESCO Finland
Immunization
7.1
6.9
16
25
B99
ICD-10 Finland
Other and unspecified infectious diseases
17.7
6.8
10
6
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
3.2
6.8
38
144
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
5.1
6.6
20
44
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.5
6.3
74
434
NEA10
NOMESCO Finland
Exploration of soft tissue of pelvis, percutaneous
28.0
6.3
8
*
2051A
ICD-9 Finland
Myeloid leukaemia, Chronic
+∞
6.3
6
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.4
6.2
31
108
C03CA01
ATC
furosemide; systemic
2.6
6.1
55
278
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
58
0
+∞
65.81
16.6
0.0
—
—
—
0
0
106
557
4.49
15.02
17.0
7.1
1.2
1.2
mmol/l
0.53
95
467
16
20
8.88
12.13
1.1
1.4
—
—
—
0
0
48
167
3.82
12.02
4.1
2.3
20.9
23.9
%
0.88
39
144
18
27
7.48
11.76
1.5
1.1
—
—
—
0
0
13
17
8.31
9.43
5.5
3.5
2.8
4.9
e9/l
2.13
13
17
13
19
7.43
8.59
5.5
3.5
51.3
56.9
%
0.57
13
19
57
273
2.81
7.94
2.9
2.0
2.4
3.1
mg/l
2.12
52
236
12
18
7.19
7.73
1.1
1.4
—
—
—
0
0
12
18
7.19
7.73
3.4
6.3
—
5348.0
—
0
5
10
16
6.64
6.04
1.0
1.1
—
—
—
0
0
17
53
3.51
4.79
1.6
2.6
7.4
7.4
g/l
—
9
39
17
53
3.51
4.79
1.6
2.6
—
—
—
0
0
17
53
3.51
4.79
1.5
2.6
3.7
3.7
g/l
—
9
37
16
48
3.63
4.76
1.6
2.7
3.4
3.1
g/l
—
9
38
13
34
4.11
4.65
1.5
1.3
—
—
—
0
0
16
50
3.48
4.49
1.5
2.6
8.1
10.0
g/l
—
10
43
11
26
4.50
4.44
1.9
1.4
—
—
—
0
0
68
450
1.97
3.86
2.4
1.9
86.1
95.6
pmol/l
0.74
45
236
67
444
1.96
3.76
5.1
3.2
—
—
—
0
0
57
366
1.93
3.45
5.9
2.2
186.5
235.4
u/l
0.33
57
351
9
19
4.98
3.29
1.0
1.2
—
—
—
0
0
6
7
8.88
3.29
1.0
1.1
—
—
—
0
0
27
136
2.21
3.11
2.7
1.9
—
—
—
0
0
11
36
3.23
2.87
1.7
2.1
—
—
—
0
0
11
36
3.23
2.87
1.5
1.6
—
—
—
0
0
11
36
3.23
2.87
1.5
1.6
—
—
—
0
0
26
135
2.13
2.78
2.8
1.9
—
—
—
0
0
37
220
1.92
2.74
3.9
3.0
2.5
2.5
mmol/l
0.15
37
198
6
10
6.20
2.72
5.0
2.5
—
—
—
0
0
6
10
6.20
2.72
1.7
1.6
175.0
170.0
u/l
—
6
10
34
197
1.95
2.71
5.3
2.7
3.1
2.5
e6/l
0.13
21
106
32
189
1.89
2.40
2.6
2.0
—
—
—
0
0
5
8
6.43
2.39
1.0
1.0
—
—
—
0
0
25
139
1.97
2.23
11.4
7.8
-0.3
1.2
mmol/l
0.54
18
111
38
244
1.76
2.18
3.6
2.3
—
—
—
0
0
7
21
3.45
1.99
1.1
1.5
—
—
—
0
0
7
21
3.45
1.99
1.1
1.5
—
—
—
0
0
68
519
1.59
1.98
7.6
4.1
—
—
—
0
0
6
16
3.86
1.95
1.0
1.3
—
—
—
0
0
49
348
1.62
1.91
4.9
2.8
0.4
0.6
e6/l
0.59
43
254
33
214
1.70
1.81
4.0
2.5
1.5
1.0
e6/l
0.30
21
122
7
24
3.01
1.74
1.7
1.6
—
—
—
0
0
37
250
1.65
1.74
2.0
1.7
1.5
1.3
mg/l
0.23
30
199
5
13
3.94
1.73
1.2
4.4
—
—
—
0
0
14
69
2.14
1.71
1.4
1.6
—
—
—
0
0
16
84
2.02
1.67
1.4
1.6
—
—
—
0
0
7
27
2.67
1.53
1.0
1.5
—
—
—
0
0
108
949
1.56
1.48
51.0
18.4
14.5
13.8
%
5.80
108
932
13
68
2.00
1.38
1.3
1.3
—
—
—
0
0
5
17
3.01
1.37
1.6
1.6
—
—
—
0
0
13
69
1.97
1.33
10.8
5.2
25.1
24.6
mmol/l
0.11
13
69
8
34
2.43
1.31
1.1
1.3
—
—
—
0
0
8
35
2.36
1.29
2.0
1.5
—
—
—
0
0
10
56
1.84
0.90
3.8
1.7
4.1
5.6
ug/l
—
10
51
21
161
1.36
0.56
16.3
6.6
105.7
104.2
mmol/l
0.84
21
156
5
31
1.63
0.43
2.6
1.4
—
—
—
0
0
39
447
0.82
0.43
4.5
4.0
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
62
568
1.16
0.35
4.0
3.8
0.0
0.0
estimate
—
10
104
73
683
1.14
0.29
2.7
2.8
—
—
—
0
0
25
286
0.85
0.27
2.6
2.9
0.7
0.7
ug/l
0.04
16
181
10
127
0.77
0.27
4.1
3.5
—
—
—
0
0
60
560
1.12
0.24
5.1
5.3
0.0
0.0
estimate
0.00
11
108
5
39
1.29
0.23
1.0
1.3
—
—
—
0
0
106
1026
1.13
0.21
44.1
15.6
37.8
40.0
%
2.44
83
742
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.8
—
4.2
—
0
5
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.9
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
118
1150
1.15
0.21
36.2
14.9
19.3
23.3
mg/l
0.91
106
909
12
144
0.82
0.21
8.0
8.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
5
70
0.70
0.17
4.8
3.4
62.9
46.4
%
—
5
70
59
561
1.09
0.15
3.9
3.8
0.0
0.0
estimate
—
9
112
9
108
0.82
0.13
1.4
2.8
5.2
8.7
ug/l
—
9
97
119
1207
0.92
0.10
43.6
17.7
95.0
79.9
umol/l
2.36
119
1207
46
480
0.94
0.09
2.7
3.9
22.6
40.4
ng/l
1.38
35
351
11
123
0.89
0.08
1.5
1.3
—
—
—
0
0
7
80
0.87
0.07
1.3
1.5
—
—
—
0
0
30
315
0.94
0.07
5.0
3.9
0.0
0.0
estimate
—
9
103
9
87
1.04
0.07
1.4
1.7
—
—
—
0
0
9
103
0.87
0.06
5.2
3.1
1.2
1.2
mmol/l
—
9
86
16
170
0.93
0.04
1.7
1.4
—
—
—
0
0
37
380
0.96
0.03
3.6
4.2
24.1
20.7
%
0.52
16
176
48
489
0.97
0.02
4.6
4.8
1.9
2.1
ug/l
0.24
43
428
108
1084
0.98
0.00
35.4
14.2
73.5
80.3
ml/min/173m2
2.00
99
901
20
199
1.01
0.00
1.2
1.2
18.4
44.6
iu/ml
—
6
59
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
2.3
—
—
—
0
0
0
6
0.00
0.00
0.0
4.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
114.5
—
0
6
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
6
63
0.95
0.00
3.5
2.7
0.9
1.3
%
—
6
63
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
0.00
0.0
1.9
—
—
—
0
0
8
86
0.93
0.00
1.3
1.8
—
—
—
0
0
0
8
0.00
0.00
0.0
2.0
—
52.8
—
0
8
0
9
0.00
0.00
0.0
1.8
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
2.3
—
—
—
0
0
0
8
0.00
0.00
0.0
2.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
6.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.9
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
0.6
—
0
5
0
5
0.00
0.00
0.0
3.0
—
12.5
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
4.0
—
—
—
0
0
0
7
0.00
0.00
0.0
2.4
—
—
—
0
0
0
7
0.00
0.00
0.0
2.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.9
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
2.4
—
—
—
0
0
0
8
0.00
0.00
0.0
2.3
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_CML – Chronic myeloid leukaemia
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).